# Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

> **NCT04676646** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 366 (actual)

## Conditions studied

- Hyperkalaemia
- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Sodium zirconium cyclosilicate
- **DRUG:** Placebo
- **OTHER:** Spironolactone

## Key facts

- **NCT ID:** NCT04676646
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-08
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676646, "Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04676646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*